Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome

Green, Melanie; Hiley, Crispin; Shanks, Jonathan H; Bottomley, I.C.; West, Catharine M L; Cowan, Richard A; Stratford, Ian J.

doi:10.1016/j.ijrobp.2006.08.077

Cited by 74 publications

(46 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There have only been a few studies that differentiated patients with radiation therapy sensitive prostate cancer from those with a poor outcome. In agreement with the results of our study, Green et al (25) reported that higher tumor VEGF expression on pretreatment biopsies was correlated with an adverse outcome following radiation therapy. They found that VEGF was the only significant prognostic factor in terms of disease-specific survival (p=0.035).…”

Section: Discussionsupporting

confidence: 93%

Role of Vascular Endothelial Growth Factor in Clinically Localized Prostate Cancer Treated with Radiation Therapy

Erkal¹,

Bora²,

Tepeoğlu³

et al. 2014

Balkan Med J

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 93%

Role of Vascular Endothelial Growth Factor in Clinically Localized Prostate Cancer Treated with Radiation Therapy

Erkal¹,

Bora²,

Tepeoğlu³

et al. 2014

Balkan Med J

View full text Add to dashboard Cite

“…VEGF is overexpressed in a variety of hematological malignancies (Krejsgaard et al 2006) and the vast majority of solid tumors, including PCa (Wegiel et al 2005) (Fig. 1), where it is associated with poorer outcomes (Duque et al 1999, Green et al 2007. In PCa, in addition to its expression in blood and lymphatic endothelial cells, VEGF is also expressed at low levels in prostatic glandular epithelial cells and in nonvascular cells, such as macrophages, fibroblast cells, and mast cells (Hrouda et al 2003).…”

Section: Transcriptional Regulation Of Pro-angiogenesis Pathways In Pcamentioning

confidence: 99%

“…High tumor VEGF levels have been associated with poor treatment outcomes in PCa, and higher VEGF serum levels have been described in patients with metastatic disease than in those with localized disease (Duque et al 1999, Green et al 2007. The use of anti-VEGF therapies in preclinical and clinical studies has been associated with increased side effects, including hypertension, gastrointestinal bleeding, intestinal perforation, and pulmonary embolism (Mangoni et al 2012, Ogita et al 2012.…”

Section: Anti-vegf Signaling Therapies In the Clinical Management Of Pcamentioning

confidence: 99%

Regulation of vascular endothelial growth factor in prostate cancer

Brot¹,

Ntekim²,

Cardenas³

et al. 2015

Endocrine-Related Cancer

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common malignancy affecting men in the western world. Although radical prostatectomy and radiation therapy can successfully treat PCa in the majority of patients, up to w30% will experience local recurrence or metastatic disease. Prostate carcinogenesis and progression is typically an androgen-dependent process. For this reason, therapies for recurrent PCa target androgen biosynthesis and androgen receptor function. Such androgen deprivation therapies (ADT) are effective initially, but the duration of response is typically %24 months. Although ADT and taxane-based chemotherapy have delivered survival benefits, metastatic PCa remains incurable. Therefore, it is essential to establish the cellular and molecular mechanisms that enable localized PCas to invade and disseminate. It has long been accepted that metastases require angiogenesis. In the present review, we examine the essential role for angiogenesis in PCa metastases, and we focus in particular on the current understanding of the regulation of vascular endothelial growth factor (VEGF) in localized and metastatic PCa. We highlight recent advances in understanding the role of VEGF in regulating the interaction of cancer cells with tumor-associated immune cells during the metastatic process of PCa. We summarize the established mechanisms of transcriptional and post-transcriptional regulation of VEGF in PCa cells and outline the molecular insights obtained from preclinical animal models of PCa. Finally, we summarize the current state of anti-angiogenesis therapies for PCa and consider how existing therapies impact VEGF signaling.

show abstract

“…The intensity of staining was evaluated by light microscopy at 400× magnification. Cytoplasmic VEGF expression was presented as a percentage of positively immunostained tumour cells (brown) in several (5)(6)(7) malignant areas of the tissue section. High-grade prostatic intraepithelial neoplasia foci and non-hyperplastic benign acini were not evaluated; however, they were stained heterogeneously.…”

Section: Immunohistochemical Assessment Of Tumour Markersmentioning

confidence: 99%

“…In the case of prostatic cancer it was shown that VEGF is connected with cell malignancy and has been linked with an adverse survival outcome [5,6]. It was also indicated that microvessel density (MVD) has been associated with tumour aggressiveness, PSA recurrence, metastatic capability after radical prostatectomy and patient survival [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Microvessel density and expression of vascular endothelial growth factor in clinically localized prostate cancer

Łuczyńska¹,

Gasińska²,

Wilk³

2013

pjp

View full text Add to dashboard Cite

Identifying biological differences between benign lesions and malignant prostatic cancer (PC) may facilitate precise indication for more aggressive post-operative treatment. Therefore, we examined immunohistochemically histological specimens from 140 PC patients treated with radical surgery. The mean age of the patients was 62.9 ±6.2 (range 49.0-77.0) years. There were 13 (9.3%) at pTNM stage 1, 78 (55.7%) at stage 2, 40 (28.6%) at stage 3 and 9 (6.4%) at stage 4. In the analysed group there were 75 (53.6%) well-differentiated, 53 (37.8 %) moderately differentiated and 12 (8.6%) poorly differentiated tumours. The mean pre-operative prostate-specific antigen (PSA) level was 9.9 ±0.5 ng/ml. Concentration of serum PSA was significantly increased with pTNM stage (p = 0.011), Gleason score (p = 0.011) and tumour grade (p = 0.003). In 34 (24.3%) tumours vascular endothelial growth factor (VEGF) expression was not shown. In the analysed group of tumours the mean percentage of positive VEGF cells was 14.8 ±1.4% and was not correlated with tumour grade (p = 0.648) or Gleason score (p = 0.697). However, significantly higher values for the protein were observed in pTNM 3 (p = 0.035) and pTNM 4 (P = 0.037) than in pTNM stage 1. In the whole series of tumours the mean microvessel density (MVD) was 97.5 ±2.4 /mm 2 . A non-significant decrease in the number of microvessels was observed in the highest pathological tumour volume (P = 0.631), Gleason score (p = 0.368) and tumour grade (p = 0.233). Prostate-specific antigen level was not associated statistically with either MVD (p = 0.466) or VEGF expression (p = 0.188). There was also no correlation between the immunohistochemical expression of VEGF and MVD (p = 0.925).

show abstract

Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome

Cited by 74 publications

References 38 publications

Role of Vascular Endothelial Growth Factor in Clinically Localized Prostate Cancer Treated with Radiation Therapy

Role of Vascular Endothelial Growth Factor in Clinically Localized Prostate Cancer Treated with Radiation Therapy

Regulation of vascular endothelial growth factor in prostate cancer

Microvessel density and expression of vascular endothelial growth factor in clinically localized prostate cancer

Contact Info

Product

Resources

About